Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2009. The report serves as a notification to the market regarding the Company's issued share capital and total voting rights as of May 31, 2009, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and contains no financial performance data.
Material Changes
The filing details the Company's share capital structure as of May 31, 2009:
- Issued Ordinary Shares: 5,662,580,322 shares of 25p each with voting rights.
- Treasury Shares: 474,194,158 Ordinary shares held in Treasury.
- Total Voting Rights: 5,188,386,164.
No comparative data for prior periods is included in this specific filing to determine material changes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document's sole purpose is to inform shareholders of the denominator to be used for calculating notification thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of voting rights (5,188,386,164) against the issued share count minus treasury shares.
- Confirm the date of the capital structure snapshot (May 31, 2009) for regulatory compliance calculations.
- Note that this filing does not contain operational or financial performance results.